Loading...
•
Mar 31, 2020
Esperion Q1 2020 Earnings Report
Esperion reported first quarter financial results, which included first-ever product sales revenue for NEXLETOL™ tablets, and provided company updates.
Key Takeaways
Esperion reported first quarter results with $1.8 million in total revenue, including $0.8 million from NEXLETOL sales and $1.0 million from collaboration revenue. The company had a net loss of $78.2 million, or $2.84 per share. They ended the quarter with $158.2 million in cash and expect an additional $150 million from Daiichi Sankyo Europe upon first commercial sale in the EU.
Company secured marketing approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe
NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30th
NEXLIZET™ (bempedoic acid and ezetimibe) Tablets Commercially Available in the U.S. on June 4th
Strong Capital Position with $158 Million in Cash and at Least $210 Million in Additional Collaboration Payments in 2020
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion updated the full-year 2020 expense guidance. Research and development expenses for the full year 2020 are now expected to be $135 million to $145 million (previously $145 million to $155 million). Selling, general and administrative expenses for the full year 2020 are now expected to be $200 million to $210 million (previously $225 million to $235 million).
Positive Outlook
- Expects an additional $150 million in cash proceeds from the Daiichi Sankyo Europe upon first commercial sale in the EU.
- Current cash resources, coupled with the expected future milestone payment under the Daiichi Sankyo Europe collaboration agreement of $150 million and NEXLETOL and NEXLIZET commercial net product sales are sufficient to fund continued operations through profitability.
- Any additional cash proceeds as a result from a ROW collaboration and the additional $50 million available to Esperion, at its option, under the Oberland Capital revenue-based funding agreement, are incremental to our path to profitably and further secures our sustainable cash runway.
- Research and development expenses for the full year 2020 are now expected to be $135 million to $145 million (previously $145 million to $155 million).
- Selling, general and administrative expenses for the full year 2020 are now expected to be $200 million to $210 million (previously $225 million to $235 million).
Challenges Ahead
- Changes result from a natural slowing of incurred expenses due to changes in planned operating expenses due to the COVID-19 environment during the first and second quarter.
- Changes result from a natural slowing of incurred expenses due to adjustments to virtual launch programs, tools and marketing tactics versus office promotional activities.
- Esperion is not providing guidance for in 2020, EU royalties, or upfront and/or milestone payment(s) from a potential Rest-of-World (ROW) agreement.
- Esperion continues to expect $30 million in non-cash stock-based compensation.
- The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
Revenue & Expenses
Visualization of income flow from segment revenue to net income